Routes to making life-saving medications and other pharmaceutical compounds are among the most carefully protected trade secrets in global industry. Building on recent work programming computers to identify synthetic pathways leading to pharmaceutically complex molecules, researchers in Poland and South Korea have unveiled computerized methods to suggest only synthetic strategies that bypass patent-protected aspects of essential drugs.
Their work appears January 17 in the journal Chem.
“When we started this project, I was somewhat skeptical that the machine would find any viable synthetic alternatives–after all, these are blockbuster drugs worth gazillions of dollars, and I was sure that the respective companies had covered the patent space so densely that no loopholes remained,” says senior author Bartosz Grzybowski, a professor of chemistry at the Ulsan National Institute of Science and Technology (South Korea) and the Polish Academy of Sciences and the lead developer of the organic synthesis software Chematica. “It turns out that the loopholes are there, and we can find new retrosynthetic pathways that circumvent the patents entirely.”
Those pharmaceutical patents protect the company’s intellectual property while also preventing competitor companies from using certain key synthetic solutions–developed painstakingly by experiment to maximize yield, increase purity, and reduce costs–when attempting to produce desired compounds. To get to viable unpatented options, the researchers “froze” challenging portions of each target molecule, forcing the computer to substitute unconventional yet chemically plausible approaches on the basis of mechanistic rules. They tested their system out on three notable commercial medicines with different chemical hurdles: linezolid, a last-resort antibiotic; sitagliptin, an antidiabetic drug; and panobinostat, a multiple myeloma treatment.
In each case, when allowed to run without constraints, the program recommended the commercial syntheses. But when even a few atoms and bonds were designated as untouchable, it innovated by applying Chematica’s existing functions to propose new plans that neatly avoided those already patented. “By algorithmically locating the key bonds on which patents hinge and propagating them down Chematica’s retrosynthetic trees, we can generate synthetic solutions from alternative yet economical starting materials, achieving a real practical impact,” Grzybowski says.
Chematica’s patent-dodging abilities could also alter how chemists approach intellectual property and patent law. For example, machine-aided searches could be used to restrict many different parts of a target molecule, lumping radically different syntheses into a single airtight patent. According to Grzybowski, however, such a patent would not necessarily stay loophole-free forever, thanks to the likely future experimental discovery of novel reactions driving chemical knowledge forward through healthy competition.
Overall, the researchers hope that their software will aid pharmaceutical companies in better protecting their intellectual property and, simultaneously, will help accelerate research and development in organic chemistry by supplying synthetic routes that differ from standard approaches. “This work illustrates the benefits of pushing chemists to think algorithmically and asking computer scientists to grasp key chemical concepts, delivering chemical artificial intelligence results that matter beyond the confines of academia,” adds co-author Piotr Dittwald, a research fellow with training in mathematics and computer science.
The Latest on: Pharma patents
via Google News
The Latest on: Pharma patents
- Opioids Drug Market by Top Key Players: Purdue Pharma, J&J, Teva, Mylan on February 7, 2019 at 4:25 am
Market competition is not intense. Purdue Pharma, J&J, Teva, Mylan, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the m... […]
- Altan Pharma Submits New Drug Application for Acetaminophen Solution for Infusion for Treatment of Pain and Reduction of Fever on February 7, 2019 at 4:01 am
These patents will provide protection for Altan’s intravenous ... patients and payors”. About Altan Pharma Ltd. Altan Pharma Ltd. is a privately held, specialty pharmaceutical company that develops, m... […]
- Harrow Health Subsidiary, Mayfield Pharmaceuticals, Inc., Acquires Patented Dyspareunia Drug Candidate and Other Intellectual Property on February 7, 2019 at 4:00 am
Mayfield Pharmaceuticals, Inc., has acquired drug formulation assets and intellectual property, including three recently issued patents, from Elle Pharmaceutical, LLC, for MAY-44, a drug candidate ... […]
- Patents in the Crosshairs During House Drug Pricing Debate on February 6, 2019 at 2:17 pm
Look for these smaller companies to produce more than a third of the new drugs approved, with a greater likelihood that they’ll undertake the marketing without a pharma partner. It’s a pretty good bet ... […]
- Actinium Provides Patent Portfolio Update for its Iomab-ACT Next-Generation CAR-T Lymphodepletion Program on February 6, 2019 at 10:00 am
The patent estate related to Iomab-ACT covers composition of ... developing the program and extending our technological lead in this area." About Actinium Pharmaceuticals, Inc. Actinium Pharmaceutical... […]
- Palleon Pharmaceuticals Announces Successful Defense of European Patent on February 6, 2019 at 4:00 am
Palleon Pharmaceuticals, a leading biotech company developing drugs that target glyco-immune checkpoints to treat cancer, today announced that the company, together with the University of Dundee, has ... […]
- Pharmalittle: Senate committee ‘reinvites’ big drug makers to testify; can pharma use AI to solidify patents? on February 5, 2019 at 6:27 am
Good morning, everyone, and how are you today? We are doing just fine, thank you, especially now that relatively balmy temperatures have unexpectedly descended on the Pharmalot campus. Although we are ... […]
- Pressure piles on US pharma and biotech IP owners on February 4, 2019 at 4:07 pm
A perfect storm of economic woes and political pressures mean that US pharma patents are under greater threat than ever before. Adam Houldsworth speaks to key industry figures about how innovators nee... […]
- Par Pharma Seeks To Void Merck Diabetes Drug Patent on February 4, 2019 at 4:01 pm
Law360 (February 4, 2019, 6:48 PM EST) -- Par Pharmaceutical Inc. asked a New Jersey federal court on Friday to invalidate the patent backing Merck’s Janumet XR so it can begin to market a generic equ... […]
- Global Pharma Giant Merck Wins US Blockchain, AI Patent for Product Authenticity on January 31, 2019 at 8:07 am
Merck, the world’s oldest pharma firm, has won a USPTO blockchain patent that aims to increase supply chain security. Major pharma firm Merck has won a USPTO blockchain and AI patent focusing on ... […]
via Bing News